| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | 0.029 | 0.9 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | Cyclopamine | FIMM | pan-cancer | AAC | -0.025 | 0.9 |